CORT Financial Facts

Loss from operations: 3.07M
Research and development: 7.05M
See Full Income Statement

Deficit accumulated during the development stage: -326.87M
Accrued clinical expenses: 6.87M
See Full Balance Sheet

Corcept Therapeutics (CORT) Earnings

  |   Expand Research on CORT
Next EPS Date 1/27/17 *Est. EPS Growth Rate +500.0% *Last Qtr.
Average EPS % Beat Rate +187.5% Revenue Growth Rate +63.2% *Last Qtr.
Average % Move 1-Wk after EPS +10.0% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$2.6M$2.7M N/A Details
8/8/13 Q213 -$0.10-$0.11 +$0.01$1.9M$2.72M N/A Details
5/3/12 Q112 -$0.13-$0.11 -$0.02N/AN/A N/A Details
8/7/12 Q212 -$0.09-$0.11 +$0.02N/AN/A N/A Details
3/5/14 Q413 -$0.11-$0.10 -$0.01$4.1M$4.01M N/A Details
11/10/10 Q310 -$0.10-$0.10 $0.00N/AN/A N/A Details
11/7/11 Q311 -$0.08-$0.10 +$0.02N/AN/A N/A Details
5/4/11 Q111 -$0.09-$0.10 +$0.01N/AN/A N/A Details